Oculis Holding AG – Filings and Transcripts

NASDAQ: OCS
Share price (9/28/26): $9.06
Market cap (9/28/26): $525 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/25 FY 2025

ended 12/31/24 FY 2024

ended 12/31/23 FY 2023

ended 12/31/22 FY 2022

ended 03/02/23 FY 2022

Prospectuses and Registrations Filter

Registration of securities for employees

Automatic shelf registration

Updated info for already-effective prospectus

Prospectus supplement

Shelf registration

Ownership Filter

LSP 7 Cooperatief U.A.

Pivotal bioVenture Partners Fund I, L.P.

Ackermann Christina

News Filter

Signs Asset Purchase Agreement With Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

Unaudited Condensed Consolidated Interim Financial Statements

Investor Presentation

Announces Topline Results From DIAMOND Phase 3 Trials With OCS-01 in Diabetic Macular Edema

Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to Its Board of Directors

Proxies

No filings in this category.

Other Filter

Notice of effectiveness

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Notice of effectiveness